Разработка методов для неинвазивной диагностики рака предстательной железы
Диссертация
В настоящее время во многих клиниках активно развивается молекулярная диагностика онкологических заболеваний, в том числе и рака предстательной железы. Преимущество данной системы диагностики перед традиционными методами заключается в том, что она позволяет диагностировать рак на ранних стадиях. Самый распространенный тест для диагностики РПЖ, основанный на определении простат-специфического… Читать ещё >
Содержание
- ГЛАВА 1. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. Введение
- 1. 2. Морфологические, гистологические и цитохимические аспекты патологических состояний предстательной железы
- 1. 3. Онкомаркеры рака предстательной железы
- 1. 4. Роль системы глутатиона в регуляции опухолевого роста
- 1. 5. Биологические свойства, структура и функции хепсина
- 1. 6. Подходы к повышению эффективности диагностики и прогнозирования РПЖ
- ГЛАВА 2. МАТЕРИАЛЫ И МЕТОДЫ
- 2. 1. Забор биологических образцов
- 2. 2. Клеточные линии
- 2. 3. Пробоподготовка
- 2. 4. Определение метилирования промоторной области гена глутатион-S-трансферазы класса Р
- 2. 4. 1. Реактивы
- 2. 4. 2. Выделение геномной ДНК
- 2. 4. 3. Метабисульфитная конверсия
- 2. 4. 4. ПЦР-амплификация
- 2. 5. Определение активности белка хепсина в моче пациентов с хроническим простатитом, с подозрением на рак предстательной железы и здоровых доноров
- 2. 5. 1. Выбор клеточной линии в качестве положительного контроля
- 2. 5. 2. Определение концентрации белка в растворе
- 2. 5. 3. Определение активности хепсина в образцах мочи и клетках линии LnCaP
- 2. 5. 3. 1. Постановка реакции
- 2. 5. 3. 2. Расчет активности фермента
- 6. Статистическая обработка результатов
- 3. 1. Определение метилированного статуса промоторного участка гена gstpl в разных биологических жидкостях при различных патологиях предстательной железы
- 3. 2. Подбор условий для исследования метилирования промоторной области гена gstpl
- 3. 3. Оценка различных методов забора биоматериала для исследования метилирования промоторной области гена gstpl
- 3. 4. Определение частоты метилирования промоторной области гена gstpl при различных патологических состояниях предстательной железы
- 3. 5. Оценка диагностической точности метода мет-ПЦР при исследовании метилирования промоторной области гена gstpl
- 3. 6. Разработка метода определения активности сериновой протеазы хепсин
- 3. 7. Анализ и оценка активности хепсина у больных с различными патологиями предстательной железы
- 3. 8. Определение предсказательной ценности положительного теста, предсказательной ценности отрицательного теста и диагностической точности метода измерения активности хепсина
Список литературы
- Аляев Ю.Г., Винаров А. З., Безруков Е.А.: Рак предстательной железы. Врач: научно-практический и публицистический журнал. 2003 — М.: № 10. — С. 24−2
- Бормотин А.В., Говоров А. В., Пушкарь Д. Ю. Алгоритм ранней диагностики рака предстательной железы. Русский медицинский журнал. 2003- М.: № 8.
- ВелиевЕ.И. Ранняя диагностика локализованных форм рака предстательной железы. Журнал «Ремедиум» 2004- 3
- Гарин A.M. Факты, достижения и неудачи современной онкологии. Алма-Ата: Казахстан, 1980.
- Залуцкий И.В., Жаврида Э. А. Алгоритмы диагностики и лечения злокачественных новообразований, — Минск. 2007. -510 с
- Заридзе Д. Г. // Арх. пат. — 1996. — Вып. 3. С 49.
- Заридзе Д.Г. Эпидемиология, механизмы канцерогенеза и профилактика рака // 1П съезд онкологов и радиологов СНГ. -Материалы съезда, Ч.1.- Минск, 2004.- С.42−46.
- Киселев В.И., Ляшенко А. А. Молекулярные механизмы регуляции гиперпластических процессов. Москва. — 2005. -348 с.
- Мазо Е.Б., Мешков В.В.- Простатическая интраэпителиальная неоплазия. -М., Гэотар Медицина 2001 г. — 80 с.
- Матвеев Б.П., Бухаркин Б. В., Матвеев В. Б. Рак предстательной железы М. — 1999, — 153с.
- Патрушев Л.И. Экспрессия генов, М., Наука. 2000 г. — 528 с.
- Ригельман Р. Как избежать врачебных ошибок. Книга практикующего врача / Пер. с англ. М.: Практика, 1994.
- Руднов В.А. Пути оптимизации диагностики, прогноза и интенсивной терапии сепсиса с органной дисфункцией автореф. диссертации. Екатеринбург- 1995.
- Сивков А.В., Аполихин О. И. Рак предстательной железы http://wwvv.uro.ru/society/plenum/cancer.php3.-2002
- Трапезников Н. Н., Кушлинский Н. Е. «Потенциальный убийца номер один» Вестник Российской академии наук, том 71, № 6. с. 503−509,2001 г.
- Черешнев В.А., Гусев Е. Ю. Системное воспаление как иммунопатобиологический феномен. Цитокины и воспаление 2002- Т.1(2): 17.
- Чиссов В.И., Дарьялова C.JI. Клинические рекомендации. Онкология. М. — 2008. — 720с.
- Abrahamsson P.A. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer. 1999 Dec-6(4):503−19.
- Arnold J. Т., Isaacs J. T. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell’s fault Endocrine-Related Cancer (2002) 9 61−73 не использовала в ссылках
- Balk SP, Ко YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003−21:383−91
- Barclay L. End of an Era for PSA Screening: A Newsmaker Interview With Thomas Stamey, J Urol. 2004−172(4, part 1 of 2):1297−1301
- Baron E, Angrist A. Incidence of occult adenocarcinoma of the prostate after 50 years of age. Archives of Pathology. 1941- 32:78 793.
- Bean M., Yatani R., Liu P. et al. Prostatic carcinoma at autopsy in Hiroshima Nagasaki Japanese // Cancer. 1973. — Vol. 32. — P. 498.
- Berenblum I. Carcinogenesis as a Biological Problem. -Amsterdam: North Holland Publ., 1974. P. 204.
- Birchmeier, C., W. Birchmeier, E. Gherardi & G. F. Vande Woude: Met, metastasis, motility and more. Nat RevMol Cell Biol, 4, 91 525 (2003)
- Bolduc S., Lacombe L., Naud A., Gregoire M., Fradet Y., Tremblay R. R. Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. CUAJ 2007- 1:377−81.
- Bostwick D.G. Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Eur. Urol. 1996−30(2):145−52. Review.
- Buchanan G., Greenberg N.M., Scher HI, et al. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001−7:1273−81.
- Carter B.S., Beaty Т.Н., Steinberg G.D., Childs В., Walsh P.C. Mendelian inheritance of familial prostate cancer. Proc Natl Acad SciU S A. 1992 Apr 15−89(8):3367−71.
- Carter B.S., Steinberg GD, Beaty TH, Childs B, Walsh PC. Familial risk factors for prostate cancer. Cancer Surv. 1991−11:5−13. (нет полного текста)
- Catalona W.J., Smith D.S., Ratliff T.L., Basler J.W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993−270:948—54.
- Chautard D.,. Daver A, Mermod В., Tichet A., Bocquillon V., Soret J.-Y. Values for the Free to Total Prostate-Specific Antigen Ratio as a Function of Age: Necessity of Reference Range Validation Eur Urol 1999−36:181−186
- Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004−10:33−9.
- Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004−10:33−9.
- Chen, Z., Z. Fan, J. E. McNeal, R. Nolley, M. C. Caldwell, M. Mahadevappa, Z. Zhang, J. A. Warrington & T. A. Stamey: Hepsin and rnaspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol, 169, 1316−9 (2003)
- Cho S-G, Lee Y.H., Park H-S., Ryoo K., Kang K.W., et al. 2001. Glutathione S-transferase Mu modulates the stressactivated signals by suppressing apoptosis signal-regulating kinase 1. J. Biol.Chem. 276:12 749−55
- Coley C.M., Barry M.J., Fleming C., Mulley A.G. Clinical guideline: Part I. Early Detection of Prostate Cancer. Part I: Prior Probability and Effectiveness of Tests. Ann Intern Med 1997−126:394−406.
- Coombs G.S., Bergstrom R.C., Pellequer J.L., Baker S.I., Navre M., Smith M.M., Tainer J.A., Madison E.L., Corey D.R. Substrate specificity of prostate-specific antigen (PSA). Chemistry & Biology September 1998, 5:475−488
- Costa J., Prostate Cancer Screening in the PSA Era. Northeast Florida Medicine2007, Vol. 58, No. 1
- Dano, K., N. Behrendt, G. Hoyer-Hansen, M. Johnsen, L. R. Lund, M. Ploug & J. Romer: Plasminogen activation and cancer. Thromb Haemost, 93, 676−81 (2005)
- Davie, E. W., Fujikawa, K., and Kisiel, W. (1991). The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30, 10 363−10 370.
- Debes J.D., Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004−351:1488−90.
- Dhanasekaran, S. M., T. R. Barrette, D. Ghosh, R. Shah, S. Varambally, K. Kurachi, K. J. Pienta, M. A. Rubin & A. M. Chinnaiyan: Delineation of prognostic biomarkers in prostate cancer. Nature, 412, 822−6 (2001)
- Dodd J.G., Paraskevas M., McNicol P.J. Detection of human papillomavirus 16 transcription in human prostate tissue // J. Urol. -1993.-Vol. 149.-P. 400.
- Dong Z.Y., Liu Y., Lu S" Wang A., Lee K., Wang L.H., Revelo M., Lu S. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endo 2006, 20:2315−2325.
- Eaton D.L., Bammler Т.К. Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol Sci. 1999 Jun-49(2): 156−64.
- Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001-! :34—45.
- Gann P.H., Hennekens C.H., Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995−273:289−94.
- Garnick M.B. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993−118:804−18
- Gelmann E.P. Molecular biology of the androgen receptor. J Clin Oncol 2002−20:3001−15.
- Gonzalgo M.L., Isaacs W.B.: Molecular pathways to prostate cancer. J Urol. 2003 Dec-170(6 Ptl):2444−52.
- Gregory C.W., Johnson R.T., Jr., Mohler J.L., et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001−61:2892−8.
- Hannappel E., Huff T. The thymosins. Prothymosin alpha, parathymosin, and betathymosins: structure and function. 2003, Vitam Horm 66:257−296
- Haritos A.A., Goodall G.J., Horecker B.L. Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus. 1984, Proc Natl Acad Sci US A 81:1008−1011
- Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005−45:51−88.
- Herbet J., Birkhoff J., Feorino P., Caldwell G. Herpes simplex virus type 2 and cancer of the prostate // J. Urol. 1976. — Vol. 116. — P. 611.
- Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996 Sep 3−93(18):9821−6.
- Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schallcen JA. DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003−44:8−16 .
- Hooper J.D., Clements J.A., Quigley J.P., Antalis T.M., Type II transmembrane serine proteases, J. Biol. Chem. 276 (2001) 857 860
- Ibrahim G.K., Gravitt P.E., Dittrich K.L. et al. Detection of human papillomavirus in the prostate by polymerase chain reaction and in situ hybridization // J. Urol. 1992. — Vol. 148. — P. 1822.
- Jiang X., Kim H.E., Shu H., Zhao Y., Zhang H., Kofron J., Donnelly J., Burns D., Ng S.C., Rosenberg S., Wang X. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. 2003, Science 299:223−226
- Jiang Z., Woda B. A, Wu C.-L., Yang X. J. Discovery and Clinical Application of a Novel Prostate Cancer Marker a-Methylacyl Co A Racemase (P504S) Am J Clin Pathol 2004−122:275−289
- Joyce, J. A. & D. Hanahan: Multiple roles for cysteine cathepsins in cancer. Cell Cycle, 3, 1516−619 (2004)
- Kirchhofer, D., M. Peek, M. T. Lipari, K. Billeci, B. Fan & P. Moran: Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-IB (HAI-1B) and HAI-2. FEBS Lett, 579, 1945−50 (2005)
- Kirschenbaum A, Itzkowitz SH, Wang JP, Yao S, Eliashvili M, Levine AC. MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage. Mol Urol. 1999−3(3): 163−168.
- Kitamoto, Y., Veile, R. A., Donis-Keller, H., and Sadler, J. E. (1995). cDna sequence and chromosomal localization of human enterokinase, the proteolytic activator of trypsinogen. Biochemistry 34,4562−4568.
- Kitamoto, Y., Yuan, X., Wu, Q., McCourt, D. W., and Sadler, J. E. (1994). Enterokinase, the initiator of intestinal digestion, is a mosaic protease composed of a distinctive assortment of domains. Proc. Natl. Acad. Sci. USA 91, 7588−7592.
- Klezovitch, O., J. Chevillet, J. Mirosevich, R. L. Roberts, R. J. Matusik & V. Vasioukhin: Hepsin promotes prostate cancer progression and metastasis. Cancer Cell, 6, 185−95 (2004)
- Knudsen, B. S. & M. Edlund: Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res, 91, 31−67 (2004)
- Kraut, J. (1977). Serine proteases: structure and mechanism of catalysis. Annu. Rev. Biochem. 46, 331−358.
- Kurachi, K., Torres-Rosado, A., and Tsuji, A. (1994). Hepsin. Methods Enzymol. 244, 100−114.
- Lai, Y., B. Wu, L. Chen & H. Zhao: A statistical method for identifying differential gene-gene co-expression patterns. Bioinformatics, 20, 3146−55 (2004)
- Lattouf J.-B., Srinivasan R., Pinto P. A., Linehan W. M., Neckers L. Mechanisms of Disease: the role of heat-shock protein 90 in genitourinary malignancy Nature Clinical Practice Urology (2006) 3, 590−601
- Lawson D. A. Witte O. N. Stem cells in prostate cancer initiation and progression J Clin Invest. 2007 August 1- 117(8): 2044−2050.
- Leytus, S.P., Loeb, K.R., Hagen, F.S., Kurachi, K., and Davie, E.W. (1988). A novel trypsin-like serine protease (hepsin) with a putative, transmembrane domain expressed by human liver and hepatoma cells. Biochemistry 27, 1067−1074.
- Light, A., and Janska, H. (1989). Enterokinase (enteropeptidase): comparative aspects. Trends Biochem. Sci. 14, 110−112.
- List, К., Т. H. Bugge & R. Szabo: Matriptase: potent proteolysis on the cell surface. Mol Med, 12, 1−7 (2006)
- Liu L, Yoon JH, Dammann R and Pfeifer GP: Frequent hypennethylation of the RASSF1A gene in prostate cancer. Oncogene 21: 6835−6840, 2002
- Lu, D., and Sadler, J. E. (1998). «Handbook of Proteolytic Enzymes.» Academic Press Ltd., London.
- Lucia M.S., Torkko K.C.: Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J Urol. 2004 Feb-171(2 Pt 2):S30−4- discussion S35.
- Luo J., Zha S., Gage W. R., et al.: a-Methylacyl-CoA Racemase: A New Molecular Marker for Prostate Cancer Cancer Res. 62, 22 202 226, April 15, 2002
- Luo, J., D. J. Duggan, Y. Chen, J. Sauvageot, С. M. Ewing, M. L. Bitt ner, J. M. Trent & W. B. Isaacs: Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res, 2001, 61, 4683−8.
- Lyons L.S., Burnstein K.L.: Vav3, a Rlio GTPase Guanine Nucleotide Exchange Factor, Increases During Progression to Androgen Independence in Prostate Cancer Cells and Potentiates Androgen Receptor Transcriptional Activity. Mol Endocrinol 2005. Dec. 29
- Mann, N. S., and Mann, S. K. (1994). Enterolcinase. Proc. Soc. Exp. Biol. Med. 206, 114−118.
- Matthews P., Jones C. J.: Clinical implications of telomerase detection Histopathology 2001, 38, 485±498
- McMenamin M.E., Soung P., Perera S., Kaplan I., Loda M., and Sellers W.R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999, 59, 4291^1296.
- McNicol P.J., Dodd J.G. High prevalence of human papillomavirus inprostate tissues // J. Urol. 1991. — Vol. 145. — P. 850.
- Mettlin C., Jones G.W., Murphy G.P. Trends in prostate cancer care in the United States, 1974—1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin 1993−43:83—91.
- Meyer HA, Alirens-Fath I, Sommer A, Haendler B. Novel molecular aspects of prostate carcinogenesis. Biomed Pharmacother. 2004 Jan-58(l):10−6.
- Mignatti, P., and Rifkin, D. B. (1993). Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73, 161−195.
- Miyamoto K. and Ushijima Т.: Diagnostic and Therapeutic Applications of Epigenetics Jpn J Clin Oncol 2005−35(6)293−301 doi:10.1093/jjco/liyi088
- Molinie V, Baumert H. New markers in prostate biopsies Actas Urol Esp. 2007−31(9): 1009−1024
- Montironi R, Bostwick DG, Bonkhoff H, Cockett AT, Helpap B, Troncoso P, Waters D. Origins of prostate cancer. Cancer. 1996 Jul 15−78(2):362−5.
- Mullins, D. E., and Rohrlich, S. T. (1983). The role of proteinases in cellular invasiveness. Biochim. Biophys. Acta 695, 177—214.
- Nelson P. S., Gleason T.P., Brawer M.K. Chemoprevention for prostatic intraepithelial neoplasia // Eur. Urol. 1996. — Vol. 30. -P. 269−278.
- Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer. N Engl JMed 2003−349:366−81.
- Nelson, W. G., De Marzo A.M., Isaacs W. B. Prostate Cancer. N Engl JMed 2003−349:366−81.
- Neurath, H. (1986). The versatility of proteolytic enzymes. J. Cell. Biochem. 32, 3519.
- Nijs H.G., Essink-Bot M.L., DeKoning H.J., Kirkels W.J., Schroder F.H.: Why Do Men Refuse or Attend Population-Based Screening for Prostate Cancer? The Journal of Urology 2000, Volume 168, Issue 2, Pages 883 883.
- Olek A., Oswald J., Walter J.: A modified and improved method for bisulphate based cytosine methylation analysis Nucleic Acids Research, 1996, Vol. 24, No. 24
- Overall, С. M. & C. Lopez-Otin: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer, 2, 657−72 (2002)
- Parr С., Jiang W.G.: Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer. 2006 Sep 1−119(5):1176−83.
- Perera F. P. // Cancer Epidemiology and Prevention / Eds D. Schottenfeld, J. Fraumeni. — New York, 1996. — P. 406—417.
- Pienta K. J., Bradley D. Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer Clinical Cancer Research Vol. 12, 1665−1671, March 2006
- Rawlings N.D., Barrett A.J., MEROPS: the peptidase database, Nucleic Acids Res. 27 (1999) 325- 331
- Rein Т., DePamphilis M. L., Zorbas H.: Identifying 5-methylcytosine and related modifications in DNA genomes Nucleic Acids Research, 1998, Vol. 26, No. 10 2255−2264
- Richie J.P., Catalona W.J., Ahmann F.R., Hudson M.A., Scardino P.T., Flanigan R.C., et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993−42:365—74.
- Riegman PH, Vlietstra RJ, Suurmeijer L, Cleutjens CB, Trapman J. Characterization of the human kallikrein locus. Genomics. 1992 Sep-14(l):6-ll.
- Rooseboom M., Commandeur J. N. M., Vermeulen N. P. E.: Enzyme-Catalyzed Activation of Anticancer Prodrugs. Pharmacol Rev 56:53−102,2004
- Sanford E., Geder L., Laychock A. et al. Evidence of the association of cytomegalovirus with carcinima of the prostate // J. Urol. 1977. -Vol. 118.-P. 789.
- Sarkar F.H., Sakr W.A., Li Y.W. et al. Detection of human papillomavirus (HPV) DNA in human prostatic tissues by polymerase chain reaction (PCR) // Prostate. 1993. — Vol. 22. — P. 171.
- Schalken JA, Hessels D, Verhaegh G.: New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology. 2003 Nov-62(5 Suppl 1):34−43.
- Schmidt J.D., Mettlin C.J., Natarajan N., Peace B.B., Beart R.W. Jr., Winchester D.P., et al. Trends in patterns of care for prostat ic cancer, 1974—1983: results of surveys by the American College of Surgeons. J Urol 1986−136:416−21.
- Shan K., Palma L., Murphy G. The occurrence of SV40 neutralizing antibodies in sera of patients with genitourinary carcinoma // J. Surg. Oncol. 1971. — No. 3. — P. 443.
- Sheikh S. S., Romanska H. M., Abel P., Domin J., Lalani N. Predictive Value of PTEN and AR Coexpression of Sustained Responsiveness to Hormonal Therapy in Prostate Cancer-—A Pilot Study Neoplasia. 2008 September- 10(9): 949−953.
- Shi X.B., Ma A.H., Xia L., et al. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002−62:1496−502.
- Silman A.J., Hochberg M.C. Epidemilogy of rheumatic disease. — Oxford: Oxford University Press., 1993.
- Singal R., Ferdinand L., Reis I. M., Schlesselman J. J.: Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncology Reports 12: 631 637, 2004
- Sloane, B. F., S. Yan, I. Podgorski, В. E. Linebaugh, M.L. Cher, J. Mai, D. Cavallo-Medved, M. Sameni, J. Dosescu & K. Moin: Cathepsin В and tumor proteolysis: contribution of the tumor microenvironment. Semin Cancer Biol, 15, 149−57 (2005)
- Srikantan V, Valladares M, Rliim JS, Moul JW, Srivastava S. HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res. 2002 Dec l-62(23):6812−6.
- Sternlicht, M. D. & Z. Werb: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol, 17, 463−516 (2001)
- Stroud, R. M. (1974). A family of protein-cutting proteins. Sci. Am. 231,74−88.
- Taille A., Vacherot F., Salomon L., Druel C., Gil Diez de Medina S., Abbou C., Buttyan R., Chopin D. Hormone-refractory prostate cancer: a multi-step and multievent process Prostate Cancer and Prostatic Diseases (2001) 4, 204−212
- Tanimoto, H., Yan, Y., Clarke, J., Korourian, S., Shigemasa, K., Pannley, Т. H., Parham, G. P., and TJ, О. B. (1997). Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res. 57, 2884−2887.
- Taplin M. E, Balk S.P. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004−91:483−90.
- Torres-Rosado, A., KS, O. S., Tsuji, A., Chou, S. H., and Kurachi, K. (1993). Hepsin, a putative cell-surface serine protease, is required for mammalian cell growth. Proc. Natl. Acad. Sci. USA 90,7181−7185.
- Townsend D.M. and Tew K.D.: The role of glutathione-S-transferase in anti-cancer drug resistance Oncogene (2003) 22, 7369−7375.
- Tsuji, A., Torres-Rosado, A., Arai, Т., Le Beau, M. M., Lemons, R. S., Chou, S. H., and Kurachi, K. (1991). Hepsin, a cell membrane-associated protease. Characterization, tissue distribution, and gene localization. J. Biol.'Chem. 266, 16 948−16 953.
- Uhland, K.: Matriptase and its putative role in cancer. Cell Mol Life Sci, 63, 2968−78 (2006)
- Vasianov A.F., Romanenko A.M., Zabarko L.B. et al. Prostatic intraepithelial neoplasia and apoptosis in benign prostatic hyperplasia before and after the Chernobyl accident in Ukrane // Pathol. Oncol. Res. 1999. — Vol. 5, No. 1. — P. 28−31.
- Vu, Т. К. H., Liu, R. W., Haaksma, C. J., Tomasek, J. J., and Howard, E. W. (1997). Identification andcloning of the membrane-associated serine protease, hepsin, from mouse preimplantation embryos. J. Biol. Chem. 272, 31 315−31 320.
- Walsh P.C., Partin A.W. Family history facilitates the early diagnosis of prostate carcinoma. Cancer. 1997 Nov 1−80(9):1871−4.
- Weber M.J., Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004−91:13−25.
- Weinstein L. В., Santella R. M., Perera F. // Cancer Prevention and Control / Eds P. Greenwald, B. Kramer, D. Weed. — New York, 1995. —P. 83—110.
- Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-inediated cell adliesion to extracellular matrix components. J Cell Biol. 1995 Apr-129(l):255−65.
- Wilding G., Chen M., Gelmann E.P. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989−14:103−15.
- Wu Q, Parry G. Hepsin and prostate cancer. Front Biosci. 2007 Sep l-12:5052−9.
- Wu Q. Type II transmembrane serine proteases. Curr Top Dev Biol. 2003−54:167−206.
- Zacharski, L. R., Ornstein, D. L., Memoli, V. A., Rousseau, S. M., and Kisiel, W. (1998). Expression of the factor VII activatingprotease, hepsin, in situ in renal cell carcinoma letter. [In Process Citation], Thromb. Haemost. 79, 876−877.
- Zhao X.Y., Malloy P.J., Krishnan A.V., et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000−6:703−6.
- Zhukov, A., Hellman, U., and Ingelman-Sundberg, M. (1997). Purification and characterization of hepsin from rat liver microsomes. Biochim. Biophys. Acta 1337, 85−95.